News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Lundbeck (JOBS), Solvay Pharmaceuticals, Inc. End Research On Schizophrenia Drug
July 30, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters) - Danish pharmaceuticals group Lundbeck (LUN.CO) and Belgium's Solvay (SOLB.BR) halted development of an experimental schizophrenia drug after receiving disappointing data from a clinical trial.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 3
Europe
Lundbeck
MORE ON THIS TOPIC
Neuropsychiatric disorders
Otsuka’s drug eases symptom burden, anxiety in ADHD as FDA verdict nears
June 26, 2026
·
2 min read
·
Tristan Manalac
Pipeline
Moderna looks out to R&D ‘horizons’ as 2028 break-even goal looms
June 26, 2026
·
2 min read
·
Tristan Manalac
Insights
The Golden Triangle and the gaps: Rethinking UK biotech
June 25, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Pancreatic cancer
Revolution’s second RAS blocker doubles chemo response rate in pancreatic cancer
June 25, 2026
·
2 min read
·
Tristan Manalac
